Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies

Ulrich Ebensperger

Financial Analyst
 
share with twitter share with LinkedIn share with facebook
share via e-mail

An opportunity over the medium term?

Strategy published on 11/08/2016 | 08:59
long trade
Live
Entry price : 224.9CHF | Target : 280CHF | Stop-loss : 218CHF | Potential : 24.5%
Roche Holding Ltd. shares have returned to important technical levels around 220.1 CHF based on weekly price data. The timing seems attractive to be a buyer of this stock.
Investors have an opportunity to buy the stock and target the CHF 280.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The company is in a robust financial situation considering its net cash and margin position.
  • The company is one of the best yield companies with high dividend expectations.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • With an enterprise value anticipated at 4.1 times the sales for the current fiscal year, the company turns out to be overvalued.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ROCHE HOLDING LTD.5.20%217 022
JOHNSON & JOHNSON18.42%377 880
NOVARTIS13.23%225 650
PFIZER11.88%215 576
MERCK AND COMPANY7.68%172 423
AMGEN25.17%135 858
SANOFI8.71%124 607
BAYER19.19%115 363
CELGENE CORPORATION17.89%108 637
BRISTOL-MYERS SQUIBB COMPAN..11.72%105 250
GLAXOSMITHKLINE-2.94%98 264
NOVO NORDISK A/S16.92%96 545
ABBOTT LABORATORIES42.28%95 664
ELI LILLY AND COMPANY17.68%94 751
ASTRAZENECA15.54%86 638
ALLERGAN PLC-2.14%66 119
More Results
Financials ( CHF)
Sales 2017 53 455 M
EBIT 2017 18 264 M
Net income 2017 11 176 M
Debt 2017 9 903 M
Yield 2017 3,50%
P/E ratio 2017 18,25
P/E ratio 2018 16,61
EV / Sales 2017 4,16x
EV / Sales 2018 3,91x
Capitalization 212 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ROCHE HOLDING LTD.
Duration : Period : Day
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Duration : Period : Week
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders